VLS.AU Vita Life Sciences Ltd

Healthcare Pharmaceuticals Australian Securities Exchange
2.74 AUD
Close of Nov 1, 2026
2.15 2.90
Market cap
AUD 148M
P/E
13.7x
P/B
2.65x
ROE
39.8%
Dividend yield
4.12%
Fundamental score
4.1/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is VLS.AU undervalued?

Graham number
Price2.74
Graham value2.16
Premium26.9%

VLS.AU trades 26.9% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vita Life Sciences Ltd fundamental analysis

18 of 22 checks passed

ROE 2/2

High return on equity (39.8%), above 20%.

ROA 1/1

Return on assets (27.6%) is above the industry median (-8.9%).

Profit Consistency 2/2

Profitable for 10 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (14.9%) is above the 5-year average (9.6% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (14.9%) is below the industry median (42.8%).

Revenue Growth 2/2

Revenue grew 11.7% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (3.9%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 77.1x against interest expense, well covered.

PE vs Market 1/1

PE (13.7x) is below the market median (15.0x).

PE vs Industry 1/1

PE (13.7x) is below the industry median (21.9x).

PBV 0/1

Price to book (2.6x) is above the industry median (2.0x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 36.3, limit 22.5).

PEG 0/1

PEG on 5-year earnings growth is 1.42, above 1.

Dividend Yield 1/2

Dividend yield (4.3%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 2/2

Dividends paid without a cut of more than 10% for 11 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 58.3%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Vita Life Sciences Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vita Life Sciences Ltd

Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company offers various minerals, herbs, and superfoods. It markets its products through pharmacies and health food channels under the Herbs of Gold, VitaHealth, and VitaScience brands. Vita Life Sciences Limited was founded in 1947 and is headquartered in Mascot,…

Full company profile